z-logo
open-access-imgOpen Access
Vitamin D Metabolism and Guidelines for Vitamin D Supplementation
Author(s) -
Indra Ramasamy
Publication year - 2020
Publication title -
pubmed central
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.132
H-Index - 28
pISSN - 0159-8090
DOI - 10.33176/aacb-20-00006
Subject(s) - vitamin d and neurology , vitamin d deficiency , vitamin , medicine , vitamin d binding protein , biomarker , endocrinology , body mass index , calcifediol , physiology , chemistry , biochemistry
Vitamin D is essential for bone health and is known to be involved in immunomodulation and cell proliferation. Vitamin D status remains a significant health issue worldwide. However, there has been no clear consensus on vitamin D deficiency and its measurement in serum, and clinical practice of vitamin D deficiency treatment remains inconsistent. The major circulating metabolite of vitamin D, 25-hydroxyvitamin D (25(OH)D), is widely used as a biomarker of vitamin D status. Other metabolic pathways are recognised as important to vitamin D function and measurement of other metabolites may become important in the future. The utility of free 25(OH)D rather than total 25(OH)D needs further assessment. Data used to estimate the vitamin D intake required to achieve a serum 25(OH)D concentration were drawn from individual studies which reported dose-response data. The studies differ in their choice of subjects, dose of vitamin D, frequency of dosing regimen and methods used for the measurement of 25(OH)D concentration. Baseline 25(OH)D, body mass index, ethnicity, type of vitamin D (D 2 or D 3 ) and genetics affect the response of serum 25(OH)D to vitamin D supplementation. The diversity of opinions that exist on this topic are reflected in the guidelines. Government and scientific societies have published their recommendations for vitamin D intake which vary from 400-1000 IU/d (10-25 μg/d) for an average adult. It was not possible to establish a range of serum 25(OH)D concentrations associated with selected non-musculoskeletal health outcomes. To recommend treatment targets, future studies need to be on infants, children, pregnant and lactating women.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here